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We  have  recently  shown  that  the  BoLA-A18  variant  haplotype  (BoLA-6*01302)  is more  prevalent  than  the
BoLA-A18  haplotype  (BoLA-6*01301)  in a sample  of Holstein/Friesian  cattle  in  Kenya.  These  MHC  class
I allelic  variants  differ  by  a single  amino  acid  polymorphism  (Glu97  to  Leu97)  in the  peptide-binding
groove. We  have  previously  mapped  an  11-mer  peptide  epitope  from  the  Theileria  parva  antigen  Tp1
(Tp1214–224) that  is  presented  by BoLA-6*01301.  Crystal  structure  data  indicates  that Glu97  in the  MHC
molecule  plays  a role  in  epitope  binding  through  electro-static  interaction  with  a  lysine  residue  in position
5 of the  epitope,  which  also functions  as  an  additional  anchor  residue.  In contrast  to  expectations,  weoLA
TL epitope
heileria parva
demonstrate  that  the  amino  acid  substitution  in  BoLA-6*01302  does  not  divert  the  CTL  response  away
from  Tp1214–224. The  two MHC  molecules  exhibit  similar  afﬁnity  for  the Tp1  epitope  and  can  present  the
epitope  to  parasite-speciﬁc  CTLs  derived  from  either  BoLA  allelic  variants.  These  data  conﬁrm  that  this
BoLA  polymorphism  does  not  alter  Tp1 epitope  speciﬁcity  and  that  both  allelic  variants  can  be  used  for
Tp1  vaccine  studies.
©  2015  The  Authors.  Published  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-ND. Introduction
Theileria parva,  a protozoan parasite that causes the disease
ast Coast fever (ECF) in cattle is responsible for major economic
osses in eastern, central and southern Africa (De Leeuw et al.,
995; Mukhebi, 1992). CD8 T cells that are primed by a live T.
arva infection and treatment method (ITM) are believed to medi-
te protection to disease and several T. parva CD8 T-cell epitopes
ecognized by immune CTL have been identiﬁed (McKeever et al.,
994; Morrison et al., 1995). Unlike in malaria, the speciﬁcity of
he CTL response to this vaccine in individual cattle is skewed to
 few epitopes and most likely contributes to the observation of
train speciﬁc immunity in ECF (MacHugh et al., 2009). Vaccination
ith a cocktail of T. parva parasite isolates provides broad-spectrum
mmunity to ECF (Di Giulio et al., 2009). Armed with this informa-
ion, our research is focused on the identiﬁcation and development
f a subunit vaccine for the control of ECF.
It has been shown that ITM vaccination of Holstein/Friesian
attle homozygous for the BoLA-A18 haplotype with the Muguga
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isolate of T. parva results in approximately 70% of the CTL being
directed to a single epitope on an antigen called Tp1 (MacHugh
et al., 2009). The epitope maps to residues 214–224 (Tp1214–224) and
is presented by BoLA-6*01301 (Graham et al., 2006, 2008). A recom-
binant version of this MHC  class I molecule has been crystalized
together with the Tp1 peptide epitope, VGYPKVKEEML (Macdonald
et al., 2010). According to this model the 11-mer peptide binds
BoLA-6*01301 in a raised conformation and Glu97, an amino acid
residue located in the BoLA peptide binding groove bonds with
lysine at position 5 (P5) in the Tp1 peptide. An alanine substitu-
tion scan of the Tp1 epitope sequence revealed the C-terminus
and the P5 position as anchor residues for binding to the MHC
molecule. The BoLA-6*01301 molecule also binds nonameric pep-
tides and an alanine scan of a high afﬁnity self-peptide, TIMPKDIQL,
revealed position P2 as an additional anchor residue to P5 and the
C-terminus. This peptide binding groove appears to be quite ﬂex-
ible as a truncated 10-mer Tp1 peptide, GYPKVKEEML, also binds
to BoLA-6*01301 but it is not recognized by Tp1-speciﬁc CTL sug-
gesting the 10-mer peptide adopts a different conformation to the
11-mer (Macdonald et al., 2010).In a recent survey of more than 200 Holstein/Friesian cat-
tle in Kenya we found an A18 haplotype with a variant of the
BoLA-6*01301 allele, BoLA-6*01302, to be more prevalent than
BoLA-6*01301 (Svitek et al., 2015) and more recent BoLA-A18
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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Fig. 1. Characterization of CTL recognizing Tp1214–224 in cattle of BoLA-6*01302 and BoLA 6*01301 type. CTL from BA219 (A), BF092 (B and D), BV115 (C) were tested for lysis
of  Tp1214–224 pulsed PBMC and of T. parva (Muguga) infected cell lines (TpM). (A and B): CTL from BA219 and BF092 (BoLA-6*01302) were tested for lysis of autologous PBMC
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TL  can kill T. parva infected target cells expressing either BoLA-6*01301 (BV115 T
erformed twice with similar result.
yping indicate that the BoLA-6*01302 is more than 90% prevalent
ompared to the BoLA-6*01301 allele (data not shown). There are
wo single nucleotide differences between these alleles but only
ne translates into an amino acid substitution, Glu → Leu at posi-
ion 97 (Immuno Polymorphism Database (part: IPD-MHC): http://
ww.ebi.ac.uk/ipd/mhc/bola/align.htm). This is a change from a
egatively charged amino acid to a hydrophobic one raising con-
erns that this polymorphism could lead to a change in the primary
TL speciﬁcity in BoLA-6*01302 cattle vaccinated by ITM.
As part of a newly established East Coast fever consortium, its planned to use the Tp1 antigen as a model antigen for gener-
ting CTL in cattle with various delivery systems and adjuvants.
ecause the BoLA-6*01302 allele is much more prevalent in Euro-
ean cattle in Kenya and possibly also in other African countries,: BV115 CTL (BoLA 6*01301) and BF092 CTL (BoLA 6*01302) demonstrate that the
d BH054 TpM) or BoLA-6*01302 allele (BF092 and BA219). The experiments were
it is very difﬁcult to source sufﬁcient numbers of animals of the
BoLA-6*01301 type for experiment. Hence, we decided to eluci-
date if BoLA-6*01302 animals also generated CTL toward the Tp1
epitope and if there were any major differences in peptide–BoLA
binding assays.
2. Material and methods
2.1. Cell linesCell lines infected with T. parva were established by infection of
PBMC in vitro with sporozoites as described previously (Goddeeris
and Morrison, 1988) Cryopreserved sporozoites stabilates of the T.
parva Muguga 3308 were used for the production of infected cell
82 N. Svitek et al. / Veterinary Immunology and Immunopathology 167 (2015) 80–85
F ) BV1
c oLA-6
6
l
i
a
T
p
a
a
2
u
e
i
L
c
r
T
w
(
P
2
c
f
p
B
(
2
(
e
t
oig. 2. Strength of CTL responses using BoLA-6*01301 and BoLA-6*01302 targets. (A
oncentrations on PBMC from BF091, BH054 (BoLA-6*01301) and BF092, BA219 (B
:1  for BA219. The experiment was  performed twice with similar result.
ines. CTL lines were generated by re-stimulation of PBMC from
mmunized cattle with autologous infected cell lines (Goddeeris
nd Morrison, 1988; Steinaa et al., 2012).
Infected cell lines, BA219 TpM, BF092 TpM, BH054 TpM, BV115
pM and CTL lines BA219, BF092, BH054 and BV115 were from
revious studies (Graham et al., 2006; Wendoh et al., 2014). BA219
nd BF092 expressed the BoLA-6*01302 A18 allele whereas BH054
nd BV115 expressed the BoLA-6*01301 A18 allele.
.2. Cytotoxicity assay
Standard 4 h release assay using 51Cr-labeled target cells were
sed to measure cytotoxicity (Goddeeris & Morrison, 1988; Steinaa
t al., 2012). 51Cr was obtained from American Radiolabeled Chem-
cals, Inc., St. Louis, MO,  USA. Supernatants were counted using
umaplates in a TopCounter (PerkinElmer, Waltham, MA, USA). The
ytotoxicity was  calculated as: (experimental release-spontaneous
elease/total release-spontaneous release). Target cells were either
. parva infected PBMC or peptide pulsed PBMC. Autologous PBMC
ere pulsed with 10-fold dilutions of the Tp1214–224 CTL epitope
Mimotopes, Clayton, Victoria, Australia), and labeled with 51Cr.
BMC were washed twice in PBS before use.
.3. Production of peptide–MHC class I tetramers and ﬂow
ytometry
Generation of peptide (p)–MHC class I tetramers was per-
ormed as described in (Svitek et al., 2014). Tp1-BoLA-6*01301
–MHC tetramers were labeled with allophycyanin (APC) and Tp1-
oLA-6*01302 p–MHC tetramers were labeled with phycoerythrin
PE). Flow cytometry was performed as described in (Svitek et al.,
014). Brieﬂy, BB007 Tp1-speciﬁc CTL line was stained with FVS450
BD Biosciences), anti-CD8 ILRI monoclonal antibody ILA51 and
ither Tp1–BoLA-6*01301–APC or Tp1–BoLA6*01302-PE p–MHC
etramers or both together. Anti-IgG1-FITC was used as the sec-
ndary antibody. Flow cytometry data were acquired on a BD15 CTL, (B) BA219 CTL. Target cells: Tp1214–224 epitope was  titrated in the indicated
*01302). CTL assays were performed at a effector:target ratio of 3:1 for BV115 and
FACSCantoTM II instrument (BD Biosciences) and analyzed with
FlowJo.
2.4. Peptide–MHC class I binding assay
Tp1 binding afﬁnity assay was performed as described in (Svitek
et al., 2014) except that human 2m was used instead of the bovine
2m at the concentration of 150 nM and heavy chain concentration
of 25 nM.  BoLA-6*01301 and BoLA-6*01302 heavy chain molecules
were incubated with the Tp1 peptide at concentrations of 3.2 nM,
16 nM,  80 nM,  400 nM,  2 M,  10 M,  and 50 M.  Kd values were
calculated by Graph Pad Prism by generating a ﬁt curve using the
One Site-Speciﬁc binding equation.
2.5. Peptide prediction and logo generation
Twenty-six protein sequences from Theileria parva, including
the Tp1 sequence, were used to predict top peptide binders using
NetMHCpan 2.8 (http://www.cbs.dtu.dk/services/NetMHCpan) of
BoLA-6*01301 and BoLA-6*01302 molecules using the 11-mer pep-
tide length and the top 2% binders were used to generate the logos
with Seq2logo (http://www.cbs.dtu.dk/biotools/Seq2Logo/).
3. Results and discussion
Cattle of the BoLA-A18 serological speciﬁcity were typed using
sequence speciﬁc primer PCR, which amplify both of the BoLA-
A18 haplotype alleles, BoLA-6*01301 and BoLA-6*01302. The PCR
products were discriminated by restriction fragment length poly-
morphism, as the BoLA-6*01301 allele contains a site for PvuII not
present in BoLA-6*01302 (Svitek et al., 2015). The allele assign-
ments were further conﬁrmed by sequencing (data not shown).
First, we tested two  cattle of the BoLA-6*01302 type (BA219
and BF092), not selected to be homozygous, for generation of
CTL toward Tp1214–224 following ITM with the Muguga isolate of
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Fig. 3. Multiparametric ﬂow cytometry analysis of Tp1–BoLA-6*01301/01302 p–MHC class I tetramer TCR binding speciﬁcities. (A) lymphocytes population, (B) single cells
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opulation, and (H) double Tp1–BoLA-6*01301-APC/Tp1–BoLA-6*01302-PE+ popul
. parva (Radley et al., 1975). Antigen speciﬁc CTL lines were gen-
rated as previously described by re-stimulation of PBMC with
utologous T. parva infected lymphoblastoid cell lines (Goddeeris
nd Morrison, 1988; Steinaa et al., 2012). These were tested in
ytolytic assays using Tp1214–224 pulsed autologous PBMC, PBMC
nly, the autologous Muguga 3308 infected cell lines and a BoLA
ismatched T. parva infected cell line as target cells (Fig. 1A and
). Both animals generated robust CTL toward autologous infected
ells and the Tp1 epitope. This clearly shows that the BoLA-6*01302
nimals generate CTL to the same Tp1 epitope as BoLA-6*01301 cat-
le. Apart from the CTL assays as shown here, this was  conﬁrmedned control, (F) Tp1–BoLA-6*01301-APC+ population, (G) Tp1–BoLA-6*01302-PE+
Arrows in orange indicate origin of each gated populations.
using interferon- ELISPOT assays using peptide pulsed targets
(data not shown).
Next, we performed a CTL experiment where CTL generated
from cattle possessing one of the two  MHC  alleles were tested
on targets expressing the other MHC  allele. If there was no dif-
ference in presenting the peptide between the two MHC  types,
CTL from each type should kill infected cells of both types (Fig. 1C
and D). As seen in Fig. 1C and D, this was  the case. For simplic-
ity only one animal of each of the two  MHC  types is shown. In
Fig. 1C, BV115 CTL (BoLA-6*01301) killed infected cell lines gen-
erated from both BoLA-6*01302 animals (BA219 and BF092) to
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Fig. 4. (A) BoLA-6*01301 (blue) and BoLA-6*01302 (red) binding speciﬁcity for Tp1. Graph is depicting the curve of Tp1 concentrations up to 2 M.  The solid lines represent
the  ﬁt curves and the dashed lines indicate the concentration at which we  observe 50% folding of the BoLA molecules (Kd values). (B) Sequence logo of the amino acid
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treferences of BoLA-6*01301 (left panel) and BoLA-6*01302 (right panel) molecule
he same extent as infected BoLA-6*01301 cell lines (BV115 and
H054). Likewise, in Fig. 1D, BF092 CTL (BoLA-6*01302) killed the
oLA-6*01301 target cells equally well as the BoLA-6*01302 cell
ines. Since the target cells were parasite infected cells it leaves
he possibility that CTL speciﬁcities besides those to Tp1 could
ccount for the observed cross killing. Therefore, we  decided to
est the CTL on PBMC pulsed with different concentrations of Tp1
eptide from 10−11 M to 10−6 M (Fig. 2), which in addition to the
pitope speciﬁc response also will show the cytotoxicity at limiting
pitope concentrations, a condition which can reveal differential
inding to the MHC/peptide complex. BV115 CTL (BoLA-6*01301)
nd BA219 CTL (BoLA-6*01302) were tested on PBMC from the two
oLA-6*01301 animals (BF091, BH054), and the two  BoLA-6*01302
nimals (BF092, BA219). As seen, there were no major differences
n the ability of the CTL lines to lyse the different target cells. Similar
esults were obtained from two other CTL lines (data not shown).
he slight differences in killing proﬁle seen in Fig. 2 may  be due to
ifferences in expression levels of the MHC  molecules in different
nimals.
We  also tested the binding of two Tp1–tetramers to a CTL line
BB007) expressing BoLA-6*01301, one based on BoLA-6*01301
nd the other based on BoLA-6*01302. The Tp1214–224 epitope
etramers were labeled with different ﬂuorochromes (PE or APC).
s seen in Fig. 3, gating was sequentially performed on forward
catter (FSC)/side scatter (SSC) as a rough dead/live discrimina-
ion, then singlets followed by gating on viable cells. From this
opulation of live cells, CD8 positive/tetramer double positive cells
re shown in Fig. 3H. Clearly, the TCR expressed by BB007 bound
he two tetramers equally well. This was also the case when a
ell line expressing BoLA 6*01302 was used (data not shown).
inally, we also assayed the binding of the peptide epitope to the
wo MHC  alleles (Fig. 4A), using an ELISA binding assay previouslydescribed (Svitek et al., 2014; Sylvester-Hvid et al., 2002). These
results showed that the Kd of the binding of the peptide to the MHC
molecules were similar, 7.47 nM for BoLA-6*01301 versus 8.63 nM
for BoLA-6*01302 with no statistical signiﬁcant difference between
them.
This study shows that the polymorphism found in amino acid
position 97 of BoLA-6*01302 does not affect the priming and
generation of CTL to the known Tp1 epitope restricted by BoLA-
6*01301. It appears that the BoLA Glu97–LysP5 peptide interaction
as described by Macdonald et al. (2010) is not critical and that other
interactions between the Tp1 peptide and BoLA-6*01302 molecule
compensate for the Glu97 to Leu97 sequence polymorphism in the
peptide binding groove. Interestingly, our experimental data verify
NetMHCpan predictions that Tp1214–224 remains a strong peptide
binder of BoLA-6*01302 (data not shown).
In conclusion, animals possessing either BoLA A18 alleles, BoLA-
6*01301 or BoLA-6*01302, can be used/interchanged for studying
the CTL response to Tp1214–224 in subunit vaccine studies. Whether
this can be extrapolated to other epitopes restricted by these
alleles would have to be experimentally veriﬁed on a case-to-case
basis since it remains a possibility that the BoLA-A18 amino acid
polymorphism may  affect binding of other epitopes. We  used the
NetMHCpan server to predict the preferred amino acid at the dif-
ferent positions in an 11mer binding peptide condition and the
relative importance of each positions in the binding is illustrated in
Fig. 4B. The Logos and amino acids at anchor positions are indeed
very similar, which suggest that the two BoLA molecules will bind
similar epitopes.Conﬂict of interests
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